Trial · NCT03320330
Adverse events693
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 693
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Part A: 20 mg/kg (Phase 1) | 1 | 6 | |
| other | Abdominal distension | Gastrointestinal disorders | Part A PK: 20 mg/kg (Expansion) | 0 | 6 | |
| other | Abdominal distension | Gastrointestinal disorders | Part B: 20 mg/kg (Phase 2) | 1 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | Part A: 20 mg/kg (Phase 1) | 1 | 6 | |
| other | Abdominal pain | Gastrointestinal disorders | Part A PK: 20 mg/kg (Expansion) | 0 | 6 | |
| other | Abdominal pain | Gastrointestinal disorders | Part B: 20 mg/kg (Phase 2) | 2 | 14 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Part A: 20 mg/kg (Phase 1) | 0 | 6 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Part A PK: 20 mg/kg (Expansion) | 0 | 6 | |
| other | Activated partial thromboplastin time prolonged | Investigations | Part B: 20 mg/kg (Phase 2) | 2 | 14 | |
| other | Agitation | Psychiatric disorders | Part A: 20 mg/kg (Phase 1) | 0 | 6 | |
| other | Agitation | Psychiatric disorders | Part A PK: 20 mg/kg (Expansion) | 1 | 6 | |
| other | Agitation | Psychiatric disorders | Part B: 20 mg/kg (Phase 2) | 0 | 14 | |
| other | Alanine aminotransferase increased | Investigations | Part A: 20 mg/kg (Phase 1) | 2 | 6 | |
| other | Alanine aminotransferase increased | Investigations | Part A PK: 20 mg/kg (Expansion) | 3 | 6 | |
| other | Alanine aminotransferase increased | Investigations | Part B: 20 mg/kg (Phase 2) | 4 | 14 | |
| other | Alkaline phosphatase increased | Investigations | Part A: 20 mg/kg (Phase 1) | 6 | 6 | |
| other | Alkaline phosphatase increased | Investigations | Part A PK: 20 mg/kg (Expansion) | 1 | 6 | |
| other | Alkaline phosphatase increased | Investigations | Part B: 20 mg/kg (Phase 2) | 8 | 14 | |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Part A: 20 mg/kg (Phase 1) | 0 | 6 | |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Part A PK: 20 mg/kg (Expansion) | 1 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03320330/events